Clinical trials: Postoperative Ocular Inflammation
Conjunctivitis, Seasonal Allergic, Conjunctivitis, Giant Papillary
A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%
The objective of this study is to identify any adverse events or adverse drug reactions through post-marketing surveillance under routine clinical practice
- Conditions
- Conjunctivitis, Seasonal Allergic, Conjunctivitis, Giant Papillary, Inflammation
- Trial name
- NCT01437982
- Testing
- Loteprednol Etabonate, Prednisolone Acetate 1% Oph Susp
- Where
- South Korea
- Volunteers
- 140 people
- Sponsor
- Bausch & Lomb Incorporated
Cataracts
Modified Intraocular Lens to Reduce Eye Inflammation After Cataract Surgery in Uveitis Patients
This study will test the effectiveness of an intraocular lens treated with heparin in reducing or preventing inflammation after cataract surgery in patients with uveitis.
- Trial name
- NCT00001311
- Testing
- heparin-surface modified intraocular lens
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Eye Institute (NEI)
Inflammation
Study of Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation
The purpose of this phase 2 study is to determine if difluprednate ophthalmic emulsion is effective in the treatment of postoperative inflammation.
- Trial name
- NCT00407225
- Testing
- Difluprednate Ophthalmic Emulsion
- Volunteers
- 24 people
- Sponsor
- Sirion Therapeutics, Inc.
Cataract
Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery
The purpose of this study is to compare the effectiveness of Nepafenac Ophthalmic Suspension, 0.1% eye drops to Acular LS eye drops, used before and after cataract surgery, for treating inflammation in the eye.
- Trial name
- NCT00333255
- Testing
- Nepafenac Ophthalmic Suspension, 0.1%
- Where
- United States
- Volunteers
- 267 people
- Sponsor
- Alcon Research
Cataract Surgery
Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery
This research will evaluate the efficacy of Omidria and Dexycu, Omidria and Dextenza, and Omidria and prednisolone acetate 1% in the resolution of post-operative inflammation and pain following cataract surgery.
- Trial name
- NCT04316936
- Testing
- Omidria, Dextenza (dexamethasone ophthalmic insert) 0.4mg, Dexycu, 9% Intraocular Suspension
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Silverstein Eye Centers